Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Passes Below 200-Day Moving Average – Time to Sell?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.01 and traded as low as $0.1004. Eagle Pharmaceuticals shares last traded at $0.50, with a volume of 1,603 shares traded.

Eagle Pharmaceuticals Price Performance

The stock has a 50 day moving average of $0.61 and a 200 day moving average of $2.01. The firm has a market cap of $6.49 million, a P/E ratio of 0.42 and a beta of 0.83.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Woodcliff Lake, New Jersey, that focuses on the development, manufacturing and commercialization of hospital-administered therapies in the areas of critical care, oncology and rare diseases. Founded in 2007, Eagle has built expertise in complex injectable formulations and orphan drug designation, aiming to address unmet medical needs through both novel products and reformulated generics.

The company’s marketed portfolio in the United States includes Bendeka®, an intravenous formulation of bendamustine for certain types of leukemia and lymphoma; Beleodaq®, approved for relapsed or refractory peripheral T-cell lymphoma; and Empaveli®, a complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.